title: MicroRNA-135a-3p as a promising biomarker and nucleic acid therapeutic agent for ovarian cancer.
abstract: Ovarian cancer is the most lethal gynecologic malignancy. Recently, several molecularly targeted anticancer agents have been developed for ovarian cancer; however, its prognosis remains extremely poor. The development of molecularly targeted therapy, as well as companion diagnostics, is required to improve outcomes for patients with ovarian cancer. In this study, to identify microRNAs (miRNAs) involved in the progression of ovarian cancer we analyzed serum miRNAs in patients with ovarian cancer using miRNA array and quantitative RT-PCR and examined the anticancer properties of miRNA expression in ovarian cancer cells. In patients with ovarian cancer, high amount of miR-135a-3p in serum samples was significantly associated with favorable clinical prognosis. The amount of miR-135a-3p was significantly decreased in patients with ovarian cancer compared with patients with ovarian cysts or normal ovaries. In SKOV-3 and ES-2 human ovarian cancer cells, enhanced expression of miR-135a-3p induced drug sensitivity to cisplatin and paclitaxel and suppressed cell proliferation and xenograft tumor growth. These findings suggest that miR-135a-3p may be considered as a biomarker and a therapeutic agent in ovarian cancer.
authors.affiliation: Department of Obstetrics and Gynecology, Fukuoka University, Fukuoka, Japan.|Central Research Institute for Advanced Molecular Medicine, Fukuoka University, Fukuoka, Japan.
authors.forename: Satoshi
authors.identifier: http://orcid.org/0000-0002-7154-1512
authors.initials: S
authors.lastname: Fukagawa
authors.affiliation: Department of Obstetrics and Gynecology, Fukuoka University, Fukuoka, Japan.|Central Research Institute for Advanced Molecular Medicine, Fukuoka University, Fukuoka, Japan.
authors.forename: Kohei
authors.initials: K
authors.lastname: Miyata
authors.affiliation: Department of Obstetrics and Gynecology, Fukuoka University, Fukuoka, Japan.
authors.forename: Fusanori
authors.initials: F
authors.lastname: Yotsumoto
authors.affiliation: Department of Obstetrics and Gynecology, Fukuoka University, Fukuoka, Japan.|Central Research Institute for Advanced Molecular Medicine, Fukuoka University, Fukuoka, Japan.
authors.forename: Chihiro
authors.initials: C
authors.lastname: Kiyoshima
authors.affiliation: Department of Obstetrics and Gynecology, Fukuoka University, Fukuoka, Japan.
authors.forename: Sung Ouk
authors.initials: SO
authors.lastname: Nam
authors.affiliation: Department of Obstetrics and Gynecology, Fukuoka University, Fukuoka, Japan.
authors.forename: Haruchika
authors.initials: H
authors.lastname: Anan
authors.affiliation: Department of Obstetrics and Gynecology, Fukuoka University, Fukuoka, Japan.
authors.forename: Takahiro
authors.initials: T
authors.lastname: Katsuda
authors.affiliation: Department of Obstetrics and Gynecology, Fukuoka University, Fukuoka, Japan.
authors.forename: Daisuke
authors.initials: D
authors.lastname: Miyahara
authors.affiliation: Department of Obstetrics and Gynecology, Fukuoka University, Fukuoka, Japan.
authors.forename: Masaharu
authors.initials: M
authors.lastname: Murata
authors.affiliation: Department of Obstetrics and Gynecology, Faculty of Medicine, Kyushu University, Fukuoka, Japan.
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Yagi
authors.affiliation: Department of Obstetrics and Gynecology, Fukuoka University, Fukuoka, Japan.
authors.forename: Kyoko
authors.initials: K
authors.lastname: Shirota
authors.affiliation: Central Research Institute for Advanced Molecular Medicine, Fukuoka University, Fukuoka, Japan.|Department of Biochemistry, Faculty of Medicine, Fukuoka University, Fukuoka, Japan.
authors.forename: Shin'ichiro
authors.initials: S
authors.lastname: Yasunaga
authors.affiliation: Department of Obstetrics and Gynecology, Faculty of Medicine, Kyushu University, Fukuoka, Japan.
authors.forename: Kiyoko
authors.initials: K
authors.lastname: Kato
authors.affiliation: Department of Obstetrics and Gynecology, Fukuoka University, Fukuoka, Japan.
authors.forename: Shingo
authors.initials: S
authors.lastname: Miyamoto
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000235:genetics*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects / Q000235:genetics; D002945:Cisplatin / Q000627:therapeutic use; D005260:Female; D020869:Gene Expression Profiling / Q000379:methods; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects / Q000235:genetics; D006801:Humans; D051379:Mice; D035683:MicroRNAs / Q000235:genetics*; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000235:genetics*; D017239:Paclitaxel / Q000627:therapeutic use; D011379:Prognosis
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; C544965:MIRN135 microRNA, human; D035683:MicroRNAs; D017239:Paclitaxel; D002945:Cisplatin
keywords: Biomarker; miR-135a-3p; molecular target; nucleic acid therapy; ovarian cancer